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Gastroenterology & Hepatology, Erasmus MC University Hospital, Rotterdam, The NetherlandsQuantitative HBsAg had been suggested to be helpful in man- NA treatment. In clinical practice, serum HBsAg level should be
agement of HBV, but assays were cumbersome. The recent avail-
ability of commercial quantitative assays has restarted the
interest in quantitative serum hepatitis B surface antigen (HBsAg)
as a biomarker for prognosis and treatment response in chronic
hepatitis B. HBsAg level reﬂects the transcriptional activity of
cccDNA rather than the absolute amount of cccDNA copies.
Serum HBsAg level tends to be higher in hepatitis B e antigen
(HBeAg)-positive than HBeAg-negative patients. Among patients
with a low HBV DNA (<2000 IU/ml), HBsAg <1000 IU/ml in geno-
type D HBV infection and HBsAg <100 IU/ml in genotype B/C HBV
infection is associated with inactive carrier state in HBeAg-nega-
tive patients. The HBsAg reduction by nucleos(t)ide analogues
(NA) is not as pronounced as by interferon treatment. On pegin-
terferon treatment, sustained responders tend to show greater
HBsAg decline than the non-responders. The optimal on-treat-
ment HBsAg cutoff to predict response needs further evaluation
in HBeAg-positive patients, but an absence of HBsAg decline
together with a <2 log reduction in HBV DNA at week 12 can
serve as stopping rule in HBeAg-negative patients with genotype
D HBV infection. A rapid serum HBsAg decline during NA therapy
may identify patients who will clear HBsAg in the long-term.
There are early reports among Asian patients that an HBsAg level
of <100 IU/ml might predict lower risk of relapse after stoppingJournal of Hepatology 20
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Since the discovery of hepatitis B surface antigen (HBsAg) by
Blumberg in 1965, it has been used as the hallmark for the diag-
nosis of hepatitis B virus (HBV) infection [1]. The importance of
HBsAg quantiﬁcation was recognized early on, but initial tests
were labor intensive and thus restricted to the research setting
[2]. In addition, no treatment for HBV was available in the
1980s when those labor-intensive tests were developed and,
therefore, these tests did not become clinically relevant. Although
standard assays have been available for quantiﬁcation of serum
HBsAg for a number of years, it is the presence or absence of
HBsAg that carries a clinical meaning to most physicians [3,4].
The interest in HBsAg quantiﬁcation started with the possible
observation of its association with the level of covalently closed
circular (ccc) DNA, the template for viral replication inside the
nuclei of hepatocytes [5,6].
In recent years, many studies have been performed, addressing
the use of serum HBsAg level to monitor the natural history and
predict treatment response in chronic hepatitis B (CHB). In light
of the availability of the new data, a group of hepatologists met
in September2010 (inAsianPaciﬁcDigestiveWeek, Kuala Lumpur,
Malaysia), October 2010 (in the Annualmeeting of American Asso-
ciation for the Study of the Liver, Boston, United States) and Febru-
ary 2011 (in theAnnualmeeting of Asian Paciﬁc Association for the
Study of the Liver, Bangkok, Thailand) with the unrestricted sup-
port of F. Hoffmann-la Roche to discuss the role of serum HBsAg
quantiﬁcation in clinical practice. An independent literature11 vol. 55 j 1121–1131
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search was performed by the group members. Data were derived
from the electronic databases and the abstracts of major interna-
tional conferences. The review was based primarily on published
full manuscripts and supplemented by new data from appropriate
conference abstracts. The suggestions were based on solid evi-
dence where possible, but on their own clinical experience and
expert opinion where data were lacking. The industrial partner
did not advise nor interfere with the content of this paper. The
authors were responsible for writing the entire manuscript with-
out the assistance of amedicalwriter. Themanuscript is notmeant
to be a guideline or a position paper. The aim of this paper was to
give insight to clinicians concerning the use of serumHBsAg quan-
tiﬁcation in clinical practice and to highlight the questions that
need to be addressed by future studies.Virology of hepatitis B surface antigen
Current evidence
HBsAg is the glycosylated envelope protein of the mature HBV
virion. There are three HBsAg proteins – small (S), medium (M),
and large (L). The envelope open reading frame (ORF) contains
three in frame ‘‘start’’ codons which further divide it into pre-
S1, pre-S2, and S-ORF domains (Fig. 1). There are two HBV mRNA
transcripts, Pre-S1 mRNA, and Pre-S2/S mRNA, from which the LPolymerase
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Fig. 1. The HBV open reading frames (ORF), highlighting the overlapping
relationship between the envelope ORF and the HBV polymerase ORF.
1122 Journal of Hepatology 2011(Pre-S1) and M/S (Pre-S2 + S/S) proteins are translated, respec-
tively. HBV replication occurs via the pregenomic RNA (pgRNA),
a separate RNA transcript, and, therefore, the HBsAg secretory
pathway and the viral replication pathway can be considered as
distinct processes within the hepatocyte (Fig. 2).
As well as virions, the sera of viremic patients contain large
numbers of two types of non-infectious particles: spherical parti-
cles and ﬁlamentous forms (Fig. 2). Both types of subviral parti-
cles are composed of HBsAg. The subviral particles are secreted
at levels far in excess of mature virions, and are believed to play
a role as a decoy for humoral immunity. HBsAg may also be pro-
duced from HBV DNA integrated into the host genome (Fig. 2).
Although viral integration is not required for normal productive
hepadnaviral infection, integration of HBV DNA occurs illegiti-
mately through recombination mechanisms using host enzymes
acting on the double-stranded linear DNA form of HBV [7,8]. In
HBV infection, viral integration seems to occur early in infection.
Integrated sequences cannot provide a template for productive
viral replication as a complete genome is not present. However,
given that sequences of the S-ORF with enhancer I elements are
often present in integrated segments, HBsAg may be produced,
often as truncated subviral particles [9].
HBV is uniqueamongDNAviruses for replicating its genomevia
an RNA intermediate. The transcriptional template of HBV is the
cccDNAwhich exists in the cell nucleus as a viralminichromosome
and serves as the intrahepatic reservoir for HBV (Fig. 2). The chal-
lenge of antiviral therapy for CHB is to clear the liver of cccDNA.
HBsAg titer should theoretically reﬂect liver total cccDNA, as well
as the transcriptional activity of the cccDNA (Fig. 2). Indeed, it
has been shown that HBsAg titers can correlate with serum HBV
DNA and intrahepatic cccDNA levels, but that this may vary in
the different phases of disease [10–12]. A positive correlation has
been noted between HBsAg titer and serum HBV DNA and liver
cccDNA in most studies of HBeAg-positive patients. However, the
regulationofHBsAgproductionandsecretionappears tobediscon-
nected from that of virion production in the HBeAg-negative state
[12,13]. In HBeAg-negative patients, although serum HBsAg titer,
serum HBV DNA level and liver cccDNA level are all reduced rela-
tive to patients with HBeAg-positive CHB, HBsAg titers have been
noted to be preserved relative to serum HBV DNA and cccDNA
[12–14]. The reason for this observation is unclear, but may be
related to the presence of integrated HBV surface genome into
the host chromosome and/or a preferential control of the replica-
tive pathway over HBsAg transcription/secretion, where virion
production is inhibited but secretion of subviral particles is pre-
served [12,14]. Additional studies are needed to determine the
utility of HBsAg measurement in HBeAg-negative patients.
HBV has the added complexity of overlapping reading frames.
The envelope ORF completely overlaps the polymerase gene
(Fig. 2). Therefore point mutations in the polymerase ORF that
are selected by nucleos(t)ide analogue (NA) therapy may result
in critical changes, including stop codons, in the envelope proteins.
For example, the mutations rtA181T and rtM204I, associated with
NA resistance, can result in the stop codons sW172⁄ andW196⁄ in
the overlapping S-ORF, respectively [15]. It remains unclear
whether thesemutations,which arise as one population in a quasi-
species, affect HBsAg titers. They have been associated with
hepatocyte HBsAg retention and potential oncogenic risk [16].
Finally, from a diagnostic perspective, it is important to
appreciate that HBsAg quantiﬁcation detects all three forms of
circulating HBsAg. The antibodies used in the quantitativevol. 55 j 1121–1131
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Fig. 2. HVB lifecycle. The lifecycle of HBV, highlighting: (i) the nuclear reservoir, covalently closed circular (ccc) DNA, which is the transcriptional template for the virus; (ii)
the HBsAg secretory pathways, and (iii) the viral replication pathways. Nucleos(t)ide analogue therapy, by targeting the HBV reverse transcriptase (RT), selectively inhibits
virion production, but does not reduce HBsAg levels as cccDNA levels are preserved. IFN-based strategies, which can non-cytolytically clear hepatocytes of HBV cccDNA
infection, may therefore induce larger reductions in HBsAg.
JOURNAL OF HEPATOLOGYenzyme immunoassays target epitopes in the S protein, and are
therefore not capable of distinguishing between the different
HBsAg proteins, nor can they distinguish between virion-associ-
ated HBsAg, subviral particles and HBsAg produced from inte-
grated sequence. Currently, there are two commercialized assay
that can measure the HBsAg quantiﬁcation, the Architect QT
assay (Abbott Laboratories) and the Elecsys HBsAg II Quant assay
(Roche Diagnostic). The Architect assay can measure HBsAg level
from 0.05 to 250 IU/ml, and manual dilution is needed for mea-
surement of higher HBsAg levels. The Elecsys II assay has an auto-
matic on-board dilution with a range of HBsAg measurement
from 0.05 to 52,000 IU/ml. In a study among 611 chronic hepati-
tis B patients from 4 sites covering HBV genotype A–G, approxi-
mately 72% of samples could have HBsAg level measured on
the ﬁrst analysis by the Elecsys II assay without the need of fur-
ther manual dilution [17]. There is good correlation between the
HBsAg measurements by these 2 assays [18,19].
Natural history
HBeAg-positive chronic hepatitis B
Current evidence
In perinatally acquired HBV infection from infected mothers with
positive hepatitis B e antigen (HBeAg), immune tolerance will beJournal of Hepatology 2011induced by the HBeAg that crosses the placenta. Immune toler-
ance phase usually occurs in the initial 2–3 decades of life char-
acterized by positive HBeAg, very high HBV DNA, normal alanine
aminotransferase (ALT) levels, and minimal histologic damage
[20]. It is followed by an immune clearance phase, which may
lead to HBeAg seroconversion. However, some patients have pro-
longed but unsuccessful immune clearance with persistently ele-
vated HBV DNA and ALT levels, and these patients have a high
risk of developing liver cirrhosis.
Based on the results of two cross-sectional studies, the serum
HBsAg level was generally higher among patients in the immune
tolerance phase than in the immune clearance phase [10,11]. In
the European study comparing 30 patients in the immune toler-
ance phase versus 48 patients in the immune clearance phase,
the mean serum HBsAg level was 4.96 log IU/ml vs. 4.37 log IU/
ml, respectively [11]. In the Asian study, the mean serum HBsAg
level was 4.53 log IU/ml among patients in the immune tolerance
phase (n = 32) vs. 4.03 log IU/ml among patients in the immune
clearance phase (n = 55) [10]. One possible reason for the lower
serum HBsAg levels among patients in the immune tolerance
phase in the Asian study was the inclusion of patients with ALT
at 1–2 times upper limit of laboratory normal, which might actu-
ally represent early immune clearance. Another explanation may
be the difference in HBsAg expression related to different HBV
genotypes. In an experiment using HBV infected cell lines, HBsAgvol. 55 j 1121–1131 1123
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expression was highest among HBV subgenotype A2/Ae, followed
by A1/Aa and B2/Ba, and distantly by B1/Bj as well as C, and the
least for D [21].
In a longitudinal study including untreated CHB patients fol-
lowed up for 99 ± 16 months, serial HBsAg levels among chronic
hepatitis B patients at different stages of disease were compared
[22]. HBsAg level was persistently high at approximately 5 log IU/
ml among patients in the immune tolerance phase, and HBsAg
level tended to be very stable with a median annual decline of
0.006 log IU/ml. The HBsAg level among patients in the immune
clearance phase was approximately 4 log IU/ml, and no difference
could be detected between patients who had persistently active
disease and those who underwent HBeAg seroconversion. The
HBsAg levels also tended to be very steady among HBeAg-posi-
tive patients with active disease with a median annual decline
of 0.021 log IU/ml.
The ratio of HBsAg to HBV DNA, which reﬂects the proportion
of subviral particles to virions was very similar among all HBeAg-
positive patients. In various studies, the median HBsAg to HBV
DNA ratio ranged between 0.5 and 0.6 in all HBeAg-positive
patients, with individual patients ranging between 0.1 and 2.0
[10,11,22].
Suggestions
Serum HBsAg level is higher in the immune tolerance phase than
in the immune clearance phase. A very high HBsAg level of
approximately 100,000 IU/ml can be a supportive evidence of
immune tolerance. Hence HBsAg can provide additional informa-
tion to differentiate immune tolerance and immune clearance
when the HBV DNA is high and ALT is normal or minimally ele-
vated. HBsAg level or HBsAg/HBV DNA ratio should not be used
to predict the chance of spontaneous HBeAg seroconversion.
Challenges
More research is required to explore the rate of HBsAg reduction
on the possibility of successful immune clearance in HBeAg-posi-
tive patients. There is preliminary data suggesting lower HBsAg
level is associated with more severe liver ﬁbrosis in HBeAg-posi-
tive patients [23]. This is an important area as HBV DNA level has
no association with the severity of liver ﬁbrosis in HBeAg-positive
patients [24].
HBeAg-negative chronic hepatitis B
Current evidence
Later in life, most of the HBV infected population evolves into the
immune clearance phase, losing HBeAg and seroconverting to
antibodies to HBeAg (anti-HBe). Because of the aging of the
infected population, the prevalence of HBeAg-negative CHB
seems to be increasing worldwide [25–27]. HBeAg-negative
CHB is characterized by wide ﬂuctuation of serum HBV DNA lev-
els and biochemical activity [28]. In patients with HBeAg-nega-
tive CHB, viremia may fall below 2000 IU/ml (the threshold
identifying inactive HBV infection) even if transiently, thus for
the differential diagnosis between HBeAg negative chronic hepa-
titis B and ‘‘inactive HBV carrier’’, serial determinations of serum
ALT and HBV DNA levels are needed [29,30]. The inactive carriers
have no or mild liver histological lesions, with an excellent
survival prognosis and low incidence of cirrhosis and HCC, while
patients with HBeAg-negative CHB with ﬂuctuating activity
have more severe progression of the disease with frequent1124 Journal of Hepatology 2011development of cirrhosis [30–33]. According to the American
and European guidelines [34,35], the differentiation between
the inactive and active phases of HBeAg-negative CHB is based
on an HBV DNA cut-off set up at 2000 IU/ml. This cut-off has
led to several controversial reports [30,36–38].
Based on several longitudinal studies, HBsAg levels are higher
in patients with active HBeAg-negative CHB than in ‘‘inactive
carriers’’. A longitudinal study in Hong Kong reported, on 68
HBeAg-negative CHB patients predominantly infected with
genotypes B and C HBV and followed for over 8 years, that the
patients with an inactive disease tended to have lower HBsAg
levels than those who had active disease; 2.24 ± 1.61 log IU/ml
vs. 2.98 ± 0.88 log IU/ml, respectively (p = 0.054) [22]. In an
extended report among 103 HBeAg-negative CHB patients fol-
lowed up for a median of 11 years, serum HBsAg of 6100 IU/
ml had 75% sensitivity and 91% speciﬁcity to predict spontane-
ous HBsAg seroclearance [39].
In Taiwan where genotype B and C HBV are prevalent, a cross-
sectional study on 251 chronic hepatitis B patients showed that
mean serum HBsAg level was higher in the immune clearance
phases (3.81 log IU/ml), signiﬁcantly decreased in the inactive
carrier state (2.25 log IU/ml) and re-elevated in the reactivation
phase (2.77 log IU/ml) [40]. In another report including 390
patients who experienced spontaneous HBeAg seroconversion,
serum HBsAg level at 1 year post HBeAg seroconversion was
inversely associated with the probability of HBsAg loss in a
dose–response manner. Compared to patients with HBsAg levels
P1000 IU/ml, the rate of HBsAg loss was higher for those with
HBsAg levels of 100–999 and <100 IU/ml, with hazard ratios of
4.4 (95% conﬁdence interval, 1.1–17.0) and 24.3 (8.7–67.5),
respectively. In patients with serum HBV DNA levels <200 IU/
ml, serum HBsAg level <100 IU/ml predicted HBsAg loss within
6 years with a positive predictive value (PPV) of 45.5% and nega-
tive predictive value (NPV) of 98.6% [41].
A study performed in Italy investigated serum HBsAg levels
and their diagnostic role in genotype D HBeAg-negative HBV car-
riers: 209 carriers where prospectively followed-up for a median
period of 34.5 (6–110) months and classiﬁed as having active or
inactive infection according to the virologic proﬁle during 1 year
of monthly monitoring [42]. Serum HBsAg levels were signiﬁ-
cantly lower in inactive (56 carriers) than in active infection
(153 carriers): median values 62.12 (0.1–4068) IU/ml vs. 3029
(0.5–82,480) IU/ml, respectively (p <0.001). Among inactive carri-
ers, HBsAg serum levels were lower in 31 asymptomatic carriers
whose viremia remained persistently below 20,000 IU/ml than in
122 asymptomatic carriers with ﬂuctuations >20,000 IU/ml: 883
(0.5–7838) vs. 4233 (164–82,480) IU/ml (p = 0.002). The combi-
nation of a single measurement of HBsAg <1000 IU/ml and HBV
DNA <2000 IU/ml allowed identifying ‘‘inactive carriers’’ with a
PPV 87.9% and NPV 96.7%.
Similar results were observed in a French study performed in
122 HBeAg-negative CHB (genotypes A–E) [43]. One hundred and
two were inactive carriers (three normal ALT measurements in
1 year) and20werepatientswithHBeAg-negativeCHB.HBsAg lev-
els were lower in the 102 inactive carriers than in the 20 patients
with HBeAg-negative CHB; 3.30 ± 0.97 vs. 3.77 ± 0.11 log IU/ml,
respectively (p <0.001). At baseline, 50 of 54 (92.5%) patients
who had HBsAg 62000 IU/ml and 53 of 57 (93%) patients who
had HBV DNA 62000 IU/ml were inactive carriers. Overall, 32
patients had HBsAg 62000 IU/ml and HBV DNA 62000 IU/ml,
and all were ‘‘inactive carriers’’ (PPV 100%). Similarly, one recentvol. 55 j 1121–1131
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Turkish study found that anHBsAg level of 2040 IU/mlbest deﬁned
inactive carriers from chronic hepatitis patients during a 3-year
follow-up (sensitivity 87.2%, speciﬁcity 75.3%) [44].
Suggestions
The combination of HBsAg and HBV DNA measurements at a sin-
gle time-point might allow an accurate identiﬁcation of ‘‘true
inactive carriers’’ and prediction of HBsAg loss in the HBeAg-neg-
ative CHB population with distinct HBV genotype infection. It
seems that HBsAg <1000 IU/ml is necessary but may not be suf-
ﬁcient to identify inactive carriers with HBV genotype D infec-
tion, and HBsAg <100 IU/ml can predict HBsAg loss over time in
genotype B or C HBV-infected patients, respectively.
Challenges
The utility of this new marker needs further validation, for the
management of HBeAg-negative CHB patients, in order to better
identify those that could beneﬁt from therapy and increased sur-
vival. Better identiﬁcation of ‘‘true inactive carriers’’ or patients
with a high likelihood of HBsAg loss, who have a good survival
prognosis and need less frequent monitoring, will reduce the
costs of medical expenses. However, HBsAg may also decrease
with age and disease progression, and other clinical parameters
including HBV DNA level must be taken into consideration to
deﬁne inactive carrier state [45].Peginterferon treatment
HBeAg-positive patients
Current evidence
Serum HBsAg levels show some correlation with intrahepatic
cccDNA levels in patients with HBeAg-positive chronic hepatitis
B, and decline in HBsAg may represent decline in cccDNA
[12,22,46]. The degree of decline in HBsAg level during peginter-
feron treatment may reﬂect the efﬁcacy of peginterferon and may
provide useful information in prediction of treatment response.
In an early study by Janssen et al., serum HBsAg level has been
shown to decrease dramatically among HBeAg-positive patients
who responded to interferon therapy [47]. HBsAg level at the
end of peginterferon treatment has also been shown to be signif-
icantly lower in patients with sustained response (deﬁned as
HBeAg seroconversion and HBV DNA <2000 IU/ml) 5 years post-
treatment [48].
Current data indicate that lower baseline serum HBsAg levels
are present in patients achieving sustained response post-pegin-
terferon treatment compared to non-responders [49,50]. Early
serological response, deﬁned as low HBsAg level or greater HBsAg
decline early during treatment, has been associated with higher
HBeAg seroconversion and HBV DNA suppression 6 months
post-treatment [51]. Chan et al. reported that sustained response
(deﬁned as HBeAg seroconversion and HBV DNA 62000 IU/ml at
the end of peginterferon and/or lamivudine treatment, and that
was sustained at 12 months post-treatment) was higher in
patients who had HBsAg 6300 IU/ml at month 6 during treat-
ment (62% vs. 11% in those who had HBsAg >300 IU/ml at month
6, p <0.001) [49]. Patients having both HBsAg decline by greater
than 1 log and serum HBsAg level 6300 IU/ml at month 6 during
treatment achieved a sustained response rate of 75% compared
with 15% in those who did not have this combined responseJournal of Hepatology 2011(p <0.001). The PPV and NPV for achieving sustained response
of this combined HBsAg response were 75% and 85%, respectively.
In the phase III registration trial on peginterferon alfa-2a
treatment in HBeAg-positive patients, HBsAg level <1500 IU/ml
at week 12 and week 24 during treatment generated PPVs of
57% and 54% and NPVs of 72% and 76%, respectively, for HBeAg
seroconversion 6 months post-treatment [51]. This study also
demonstrated an HBsAg clearance rate of 17.6% at 6 months post-
treatment in patients with HBsAg level <1500 IU/ml at week 12
and HBeAg seroconversion 6 months post-peginterferon treat-
ment. The association of HBsAg and sustained HBeAg seroconver-
sion was conﬁrmed by the results of the NEPTUNE study [52].
Sonneveld et al. showed a more vigorous decline in HBsAg
level starting at week 4 of peginterferon alfa-2b treatment in
responders deﬁned as HBeAg loss with HBV DNA <2000 IU/ml
at 26 weeks post-treatment [53]. Patients who did not have any
decline in HBsAg at week 12 achieved response in only 3%. There-
fore, the NPV of the absence of any decline in HBsAg at week 12 is
97% for prediction of response 6 months post-treatment. How-
ever, the retrospective analysis from the phase III trial of pegin-
terferon alfa-2a did not conﬁrm a high NPV as in the Sonneveld
study; 18% of patients who did not have any HBsAg decline at
week 12 achieved HBeAg loss and HBV DNA <2000 IU/ml at
6 months post-treatment (NPV 82%) [54]. It is possible that differ-
ences in study population and HBV genotypes could explain why
the high NPV in the Sonneveld study was not conﬁrmed. The Son-
neveld study included mainly Caucasian patients (72%) infected
with genotype A and D HBV (35% and 39%, respectively), whilst
87% of patients in the peginterferon alfa-2a study were Asians
mainly infected with genotype B and C HBV (23% and 71%,
respectively). On the other hand, week 12 HBsAg > 20000 IU/ml
has an NPV of 84% in the peginterferon alfa-2a phase III study
and 100% in the NEPTUNE study for sustained HBeAg seroconver-
sion [51,52].
Suggestions
The decline in serum HBsAg level at weeks 12 and 24 during
peginterferon treatment can be used as a surrogate marker to
predict sustained response in patients with HBeAg-positive
CHB, and to identify patients who are unlikely to have sustained
response despite continued treatment. In general, poor HBsAg
response at week 12 can predict non-responders and good
HBsAg response at week 24 can predict good responders to
peginterferon therapy (Table 1).
Challenges
Further studies to identify and validate optimal cutoff levels of
HBsAg are needed. Furthermore, HBsAg levels and their declines
during peginterferon treatment appear to differ across HBV
genotypes, suggesting genotype-speciﬁc algorithms are required
[55–57]. More research on the management of patients with
sub-optimal HBsAg response will be needed before making
recommendations.
HBeAg-negative patients
Current evidence
Response rates of HBeAg-negative patients to peginterferon are
low, and, therefore, baseline predictors of response are important
when considering peginterferon based treatment in these
patients. Unfortunately, only one study has so far addressed thisvol. 55 j 1121–1131 1125
Table 2. Prediction of treatment response by HBsAg decline at different
phases of peginterferon therapy for HBeAg-negative chronic hepatitis B in the
phase III trial of peginterferon alfa-2a [56,59].
Time  
(week)  
HBsAg 
decline  
esnopseRn
(n, %)  
Definition of response
21 ≥10% 1raeytagol4<ANDVBH)74(5235
<10% )61(1176
≥10% 5raeytassolgAsBH)32(2135
<10% )7(576
42 ≥10% 1raeytagol4<ANDVBH)34(9276
<10% )31(735
≥10% 5raeytassolgAsBH)22(5176
<10% )4(335
3(3134gol1>84 0) HBsAg loss at year 3
≤1 log )3(4551
Table 1. Proportion of HBeAg-positive patients with sustained virological response (SVR) as predicted by serum HBsAg at week 12 and 24 of treatment. In general,
poor HBsAg response at week 12 can predict non-responders and good HBsAg response at week 24 can predict good responders to peginterferon therapy.
Author [Reference]
Prediction at week 12 Prediction at week 24 
Sonneveld ]35[
Piratvisuth [54]  
Lau ]15[
]25[enaG
Lau ]15[
]25[enaG
Chan ]94[
HBsAg 
No decline 
No decline
>20,000 IU/ml 
>20,000 IU/ml
<1500 IU/ml 
<1500 IU/ml
<300 IU/ml 
<300 IU/ml and 
>1 log decline 
% patient 
13
42
22
81
32
72
AN
AN
% SVR  
3  
18  
16  
0 
57  
58  
NA  
NA  
% patient 
52
AN
31
41
43
04
32
31
RVS%
8 
AN
15
0 
45
75
62
57
NA = not available.
Reviewclinical problem [58]. One other report of preliminary data from a
small cohort of patients treated with peginterferon alfa-2a and
adefovir showed that lower baseline HBsAg levels were associ-
ated with a sustained virological response (HBV DNA <2000 IU/
ml at 6 months post-treatment), but clinically useful cut-off val-
ues were not reported [59], and other studies were unable to con-
ﬁrm these ﬁndings [60,61].
On-treatment monitoring of HBsAg kinetics in HBeAg-nega-
tive patients treated with peginterferon may add considerably
to HBV DNA monitoring alone. This is especially relevant since
many HBeAg-negative patients treated with peginterferon
achieve undetectable HBV DNA levels during therapy, but relapse
after discontinuation [62–64]. One relatively small study by Mou-
cari et al. reported on 48 HBeAg-negative CHB patients treated
with peginterferon alfa-2a for 48 weeks [61]. Similar to HBeAg-
positive disease, patients who achieved an off-treatment sus-
tained response (deﬁned as undetectable HBV DNA 6 months
after treatment discontinuation) experienced the most pro-
nounced HBsAg declines during treatment. The authors also
showed that patients who achieved a decline of more than
0.5 log IU/ml through the ﬁrst 12 weeks of therapy had a very
high probability of response (89%), compared to a probability of
only 10% in those who failed to achieve such a decline. Similar
ﬁndings were reported for a 1 log decline at week 24.
In a retrospective analysis of HBsAg levels during treatment in
120 patients who participated in the registration trial for pegin-
terferon alfa-2a, patients who failed to achieved a decline of at
least 10% in serum HBsAg from baseline through 12 weeks of
treatment (n = 67) had a lower probability of response (16%, vs.
47% in those with a decline >10%, p <0.01) [65]. However, a con-
siderable proportion of patients who did not achieve a 10%
decline in HBsAg levels achieved HBsAg loss, limiting the clinical
utility of this cut-off as a stopping rule for peginterferon based
treatment in HBeAg-negative CHB (Table 2).
Another study among HBeAg-negative patients, predomi-
nantly infected with HBV genotype D and treated with peginter-
feron ± ribavirin, showed that monitoring of both HBV DNA and
HBsAg levels during treatment may provide more optimal predic-
tion of response than either marker alone [60]. In this study,
patients who failed to achieve both a decline in HBsAg levels as
well as a decline of >2 log in HBV DNA did not respond (response
deﬁned as HBV DNA <10,000 copies/ml and normal ALT at1126 Journal of Hepatology 20116 months post-treatment). Importantly, this possible stopping-
rule was recently validated in other cohorts of HBeAg-negative
genotype D patients treated for either 1 or 2 years with peginter-
feron alfa-2a, and its utility was conﬁrmed [66]. However, the
stopping-rule has less discriminatory capabilities in HBeAg-neg-
ative patients infected with other HBV genotypes. A possible
explanation for this discrepancy is the inﬂuence of HBV genotype
on HBsAg kinetics during treatment, as recently shown in a small
study [67], suggesting a need for genotype speciﬁc prediction
rules.
In addition to on-treatment prediction of response, one study
has investigated the use of end-of-treatment HBsAg levels as pre-
dictors of sustained off-treatment response and subsequent
HBsAg clearance [68] (Table 2). In this study, patients with HBsAg
levels <10 IU/ml (n = 23) at week 48 had a 52% probability of
HBsAg clearance through 3 years of post-treatment follow-up,
compared to only 2% in all other patients. Importantly, the pre-
dictive capabilities of HBsAg levels at week 48 were higher than
that of HBV DNA levels; of those patients with undetectable HBV
DNA at week 48 (n = 161), only 15% achieved HBsAg clearance.
Overall, patients with a HBsAg level >19 IU/ml (or a decline fromvol. 55 j 1121–1131
 n = 0 
Any HBsAg 
decline or 
HBV DNA 
decline >2 log 
Sustained 
response 
Patients
n = 102 
Both NO
n = 20  
Either YES
n = 82  
NO
n = 20  
YES NO
 n = 58 
YES
n = 24  
Predictive 
values NPV 100% PPV 29% 
Fig. 3. Flow chart on the use of HBV DNA and HBsAg to predict response to
peginterferon treatment in the PARC study.
JOURNAL OF HEPATOLOGYbaseline <0.46 log) had such a low probability of a sustained
response through 3 years of post-treatment follow-up that
retreatment in these patients with nucleos(t)ide analogues (NA)
seems warranted [65].
Suggestions
Combination of HBsAg and HBV DNA decline at week 12 of pegin-
terferon therapy could well be used as a stopping rule in clinical
practice for HBeAg-negative patients, particularly among those
infected by genotype D HBV (Fig. 3).
Challenges
The early identiﬁcation of sustained response to peginterferon
therapy (high positive predictive value) needs to be improved
in HBeAg-negative disease. The use of HBV DNA and HBsAg to
guide stopping of peginterferon in genotype B and C HBV infected
patients needs to be validated in future studies.Treatment with nucleos(t)ide analogues
Current evidence
General trend of HBsAg decline on NA therapy
Until recently only few studies have analyzed HBsAg levels dur-
ing therapy with NA [69–74]. Most studies included heteroge-
neous patient populations (e.g. transplanted patients [71] or
focused only on patients with anti-HBs seroconversion or
assessed only few time-points during NA treatment [68].
Some studies have compared HBsAg kinetics between patients
treated with interferon alfa and NA [68,70,75]. The data suggest
that HBsAg decline during NA therapy is slower and less pro-
nounced compared to interferon treatment, despite a higher
effect on HBV DNA suppression. For example, Manesis et al. com-
pared HBsAg decline during a median of 33 months of lamivudine
treatment and compared it with that observed with interferon
[70]. Patients treated with interferon showed a stronger and fas-
ter HBsAg decline than lamivudine treated patients. Based on
HBsAg kinetics, the authors estimated that the time to HBsAg loss
was around 5 years for patients with sustained response to inter-
feron compared with >10 years for lamivudine virological
responders. Other studies suggested that the predicted median
time to HBsAg loss in NA treated patients is more than 30 yearsJournal of Hepatology 2011[76,77]. Brunetto et al. analyzed 386 HBeAg-negative patients
treated either with peginterferon alfa-2a and/or lamivudine.
HBsAg decrease was stronger with peginterferon (alone or com-
bined with lamivudine; mean decline at end of treatment,
0.71 and 0.67 log IU/ml, respectively) compared to treatment
with lamivudine alone (0.02 log IU/ml) [68]. The reason for
the slow decline of HBsAg in NAs treatment is probably because
NAs inhibit only the reverse transcription of the pregenomic RNA
but do not target the cccDNA directly. Thus, changes at transcrip-
tional levels, particularly in the HBsAg secretory pathway, are not
expected. On the other hand, IFN has both direct antiviral and
immune mediated effects. It is likely that the immune modula-
tion by interferon leads to a more dramatic decline in HBsAg pro-
duction and secretion.
All studies investigating quantitative HBsAg during NA ther-
apy suggest that HBsAg decline is slower than that of serum
HBV DNA [67], even in patients who subsequently clear HBsAg
[71,72]. This may reﬂect the remaining cccDNA in the infected
hepatocytes in patients with long-term established chronic HBV
infection. This is different to the situation during acute HBV infec-
tion where HBV DNA and HBsAg decline in parallel [78]. Borgniet
et al. analyzed HBsAg kinetics in 16 patients who cleared HBsAg
during antiviral therapy. In most patients HBsAg persisted after
HBV DNA elimination from the serum for 1–5 years, with a pro-
gressive decline in titer observed. The average time to HBsAg loss
after undetectable levels of HBV DNA were achieved was
30 months [72].
HBeAg-positive patients
A very important question is whether it would be possible to pre-
dict HBsAg loss using quantitative HBsAg values during NA treat-
ment. Wursthorn et al. analyzed quantitative HBsAg in 162
HBeAg positive patients treated with telbivudine for at least
3 years [73]. All patients included had a maintained HBV
DNA <60 IU/ml after two years of therapy. Nine patients (6%)
developedHBsAg loss through the follow-upof three years. A rapid
HBsAgdecline ofmore than1 log after 1 year of treatmentwaspre-
dictive for HBsAg loss, emphasizing the value of quantitative
HBsAg formonitoring response toNA therapy. Similarly, in thepiv-
otal trial of tenofovir, patients who had HBsAg loss, tended to have
higher baseline HBsAg level and a more rapid decline in HBsAg
level as compared to thosewho failed to lose HBsAg on 4-year ten-
ofovir treatment [79,80]. Genotype A and D HBV had higher base-
lineHBsAg andmore continuous decline inHBsAg than genotype B
and C HBV. In a small study in China, among 11 HBeAg positive
patients who were treated with telbivudine for 2 years, HBsA-
g <100 IU/ml at the end of treatment predicted for sustained
response (deﬁned as undetectable HBV DNA, normal ALT and
HBeAg seroconversion) for 2 years after stopping treatment [74].
HBeAg-negative patients
Among entecavir and tenofovir treated patients, the decline in
HBsAg is less pronounced in HBeAg-negative patients than in
HBeAg-positive patients [75,79]. In a study in Hong Kong among
53 HBeAg-negative patients on lamivudine treatment for a mean
of 19 months, the end-of-treatment HBsAg levels could predict
sustained viral suppression (HBV DNA 6200 IU/ml) [81]. All ﬁve
patients who had HBsAg reduction by >1 log to 6100 IU/ml
(PPV 100%) and 4 of the 8 patients who achieved either
HBsAg 6100 IU/ml or a reduction of HBsAg by >1 log (PPV 50%)
had sustained viral suppression at 12 months post-lamivudinevol. 55 j 1121–1131 1127
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treatment. On the other hand, all 40 patients who had HBsAg
reduction by 61 log to a level >100 IU/ml could not achieve sus-
tained viral suppression at 12 months post-treatment (NPV
100%). The end of treatment HBsAg response could also predict
sustained viral suppression and HBsAg loss up to 5 years after
stopping lamivudine.
However, in another German study with predominantly
HBeAg-negative patients (67%) on NA therapy, early on-treat-
ment decline did not necessarily predict HBsAg loss [78]. Some
patients with early HBsAg decline during NA therapy might have
just changed the phase of HBV infection (i.e. transition from
immune clearance phase to HBeAg-negative hepatitis), which is
associated with different HBsAg levels [7,8]. Thus, it may repre-
sent an already ongoing natural HBsAg decline in some patients.
In contrast to interferon therapy [53,55,60,61], early HBsAg kinet-
ics alone during NA therapy may not reliably predict later HBsAg
loss. In this German cohort, HBsAg decline of more than 0.5 log in
the 2 years after virological response (deﬁned as HBV DNA
<100 IU/ml) was associated with later HBsAg loss [78]. However,
patients who received no treatment also demonstrated similar
HBsAg kinetics during the natural course of HBV infection in this
study. This suggests that NA therapy may have only a limited
impact on HBsAg suppression, explaining that HBsAg loss
remains a rare event during NA therapy. Thus, most patients trea-
ted with NA will require life-long maintenance therapy. Taking
all currently available data into account, HBsAg loss during NA
therapy may be limited to patients with more active immune
responses also supported by data showing than NA induced
HBsAg loss is associated with higher baseline ALT [76,78].
Suggestions
Overall, serum HBsAg decline is slow and does not correlate with
HBV DNA levels during treatment with NAs. However, a rapid
serum HBsAg decline during NA therapy, ideally after virological
response has been achieved, may identify patients who will clear
HBsAg in the long-term. A 6–12 monthly assessment of quantita-
tive HBsAg level can be considered to monitor NA therapy.
Among Asian patients (genotype B and C HBV infected patients),
an HBsAg level of <100 IU/ml might predict lower risk of relapse
and stopping treatment can be considered. This is based on lim-
ited evidence and further validation by larger scaled, multi-cen-
tered studies will be needed [74,81,82].
Challenges
It will be important to identify a level of serum HBsAg reduction
or a cut-off that is associated with subsequent HBsAg loss. It will
also be of interest to identify an HBsAg level that is associated
with effective immune control where termination of antiviral
therapy is possible with low risk of reactivation. Whether this
cut-off is in accordance with the one proposed for the identiﬁca-
tion of low replicative inactive HBsAg carrier remains to be deter-
mined [42,43,83]. It is also unknown if viral breakthrough due to
drug resistance affects quantitative HBsAg level as mutations in
the HBV polymerase can also involve changes in the HBsAg
[69]. As certain mutants at the surface region, which overlaps
with the polymerase region, might inﬂuence the amount of
HBsAg level detected by the Architect (Abbott) and Elecsys
(Roche) assays, it appears advisable to use the same assay for fol-
low-up of individual patients on treatment [84,85].1128 Journal of Hepatology 2011Unanswered questions and perspectives
In the recent years, increasing evidence shows that in chronic
HBV infection, serum HBsAg levels are indirectly correlated with
the control of the infection: the higher the control, the lower
serum HBsAg levels. Accordingly, serum HBsAg levels are lower
in inactive carriers than in HBeAg-negative CHB patients and
decline signiﬁcantly during effective antiviral treatment. The
information provided by serum HBsAg quantiﬁcation is different
but complementary to that of serum HBV DNA. Hence, HBsAg
quantiﬁcation should not be used as a substitute for HBV DNA
measures in clinical practice. In particular, among patients on
NA therapy, HBV DNA is used to monitor response to treatment
and emergence of drug resistance, while HBsAg level may have
a role in identifying HBeAg-negative patients suitable for one
treatment cessation.
However, until now, a precise biological understanding of
these clinical ﬁndings is missing: an overall correlation has been
suggested between serum HBsAg levels and the intrahepatic
amount of cccDNA, but this may not hold true in all the phases
of HBV infection, particularly in the HBeAg-negative phase. We
may speculate that HBsAg is the indirect expression of cccDNA
amounts and transcriptionally active cccDNA, but we need to bet-
ter understand the complex equilibrium between intracellular
HBV biology and the host’s immune system and its relations with
transcription of HBsAg speciﬁc mRNAs, HBsAg production and
secretion. Furthermore, we need to know whether HBV heteroge-
neity in terms of genotypes and ‘‘S’’ gene variability, either natu-
rally occurring or therapy induced, inﬂuences serum HBsAg levels
in clinically relevant terms. This information is needed to identify
correctly HBsAg thresholds to be used in clinical practice.
Substantial variations of serum HBsAg levels in the different
phases of HBV infection propose quantitative HBsAg as a new
diagnostic tool for the characterization of HBV carriers. However,
in spite of the different cut-offs so far identiﬁed, larger multicen-
ter studies have to be performed for their appropriate clinical val-
idation. In addition, further work is required to understand
whether monitoring serum HBsAg levels at the time of HBeAg
to anti-HBe seroconversion and their delta variations over time
might help to distinguish patients with durable seroconversion
from those with higher risk of HBeAg seroreversion. Accordingly,
HBsAg monitoring could provide a useful tool for tailoring the
duration of antiviral treatment in HBeAg positive patients. It also
remains to be analyzed if HBsAg quantiﬁcation might serve as an
indicator of viral breakthrough in patients who have become HBV
DNA negative in serum but remain HBsAg positive. In addition to
the issue of successful immune clearance, in HBeAg positive
patients, data are missing on the relationship between serum
HBsAg level and the severity of histologic grading and staging.
Overall, to improve the diagnostic accuracy in the characteriza-
tion of HBV carriers, more studies must be performed on the
combined use of quantitative HBV DNA and HBsAg as their com-
plementary information on the phases of HBV infection may be
very useful in clinical practice to deﬁne the speciﬁc condition of
the single HBV carrier during the highly dynamic phases of
chronic HBV infection. Finally it will be important to identify lev-
els of HBsAg reduction or cut-offs that are associated with the
effective immune control that brings to subsequent HBsAg loss,
therefore, allowing termination of NA therapy with the lowest
risk of reactivation. Whether this cut-off is in accordance with
the one proposed for the identiﬁcation of low replicative inactivevol. 55 j 1121–1131
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HBsAg carriers or peginterferon treated patients remains to be
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